Robin Thomma et al.

In this study, we use the biobank and clinical database of IGOS to investigate on a global scale the presence of AGAb in glyco-arrays in relation to preceding infections, clinical characteristics and subtypes, clinical course, and outcomes in patients with GBS. In addition to studying single glycolipids, the added diagnostic and categorical value of combinatorial array (i.e. heteromeric clusters of two gangliosides) over single array is investigated. All available entry or week 1 serum samples in the IGOS-2000 biobank have been tested at the University of Glasgow (Susan Halstead/Hugh Willison). Analyses have been finalized and a manuscript is in preparation.

Robin Thomma et al.

In this study, we use the biobanks and clinical databases of IGOS and several additional Dutch trial cohorts to investigate single nucleotide polymorphisms in relation to disease susceptibility and clinical features, clinical course, and outcomes in patients with GBS. Available entry or week 1 DNA samples in the IGOS-1000 biobank have been tested at the Erasmus MC in Rotterdam. Analyses are currently ongoing.

Robin Thomma et al.

In this study, we use the biobank and clinical database of IGOS to investigate the occurrence of the big five preceding infections in GBS (Campylobacter jejuni, Mycoplasma pneumoniae, cytomegalovirus, Epstein-Barr virus, and hepatitis E virus) and associated serology parameters in relation to clinical features, clinical course, and outcomes in patients with GBS. Data from IGOS-1000 have already been published (Leonhard et al, Neurology) and will be validated. All available entry or week 1 serum samples in the IGOS-2000 biobank have been tested at the Erasmus MC in Rotterdam and the Reinier Haga Medical Diagnostic Center in Delft. Analyses are currently ongoing.

Farah Pelouto et al.

In this study, we used patient-reported outcome measure data collected from various countries from IGOS-2000. Our primary aim is to validate the I-RODS, the FSS and the Rash version of the FSS (R-FSS) in patients with GBS by evaluating their measurement properties. Analyses have been conducted and finalized, and manuscripts are currently in preparation.

Eveline Wiegers & Laura de Koning et al.

In this study, we aim to characterize patients with GBS in routine clinical setting to provide a basis to personalize treatment and further identify best practices for GBS. More specific, we aim to describe patient characteristics, disease course and outcomes (including two and three year outcomes) of all patients with GBS in IGOS. The entire cohort of IGOS will be included for this study. Analyses are currently ongoing.